Cryptococcemia in a patient with COVID‐19: A case report

The authors urge clinicians to balance the use of Immunosuppressant drugs and tocilizumab for COVID‐19 patients to avoid the development of infections like Cryptococcemia, leading to death within 30 days.

Detalles Bibliográficos
Autores principales: Khatib, Mohamad Y., Ahmed, Amna A., Shaat, Said B., Mohamed, Ahmed S., Nashwan, Abdulqadir J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869327/
https://www.ncbi.nlm.nih.gov/pubmed/33598258
http://dx.doi.org/10.1002/ccr3.3668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869327/
https://www.ncbi.nlm.nih.gov/pubmed/33598258
http://dx.doi.org/10.1002/ccr3.3668

Ejemplares similares